<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-72662</identifier>
<setSpec>0300-8932</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">In-hospital outcomes associated with fibrinolytic and thienopyridine use in patients with ST-segment elevation acute myocardial infarction. The Global Registry of Acute Coronary Events</dc:title>
<dc:description xml:lang="en">Introduction and objectives. To investigate how thienopyridine treatment, with or without associated fibrinolysis, affects the rates of major bleeding and inhospital death in patients with ST-elevation myocardial infarction (STEMI). Methods. The rates of major bleeding and in-hospital death were studied in 14 259 consecutive patients with STEMI. During hospitalization, 5340 (38%) received thienopyridines, 3007 (21%) received fibrinolytic drugs, and 2044 (14%) received both. Results. Major bleeding occurred more frequently in patients who received thienopyridines with or without fibrinolytics, in 4.6% and 4.1%, respectively, compared with 2.3% in those who received fibrinolytics alone and 2.8% in those who received neither (P &lt; .001). Multivariate analysis, which included adjustments for risk factors for bleeding, percutaneous coronary intervention, and cardiac catheterization, showed that thienopyridine treatment was an independent risk factor for bleeding (odds ratio =1.68; 95% confidence interval, 1.23-2.31). In-hospital mortality was lower in patients who received a thienopyridine, and such treatment was an independent predictor of lower mortality (odds ratio =0.50; 95% confidence interval, 0.39-0.60). Conclusions. Thienopyridine treatment was associated with an increased risk of major bleeding but also with a better in-hospital prognosis. These findings in unselected patients with STEMI, who are representative of those seen in daily clinical practice, complement, but do not replace, the data obtained in randomized clinical trails of selected patients. risk factor for bleeding (odds ratio=1.68; 95% confidence interval, 1.23-2.31). In-hospital mortality was lower in patients who received a thienopyridine, and such treatment was an independent predictor of lower mortality (odds ratio=0.50; 95% confidence interval, 0.39-0.60). Conclusions. Thienopyridine treatment was associated with an increased risk of major bleeding but also with a better in-hospital prognosis. These findings in unselected patients with STEMI, who are representative of those seen in daily clinical practice, complement, but do not replace, the data obtained in randomized clinical trails of selected patients (AU)</dc:description>
<dc:creator>Dabbous, Omar H</dc:creator>
<dc:creator>Fox, Keith A. A</dc:creator>
<dc:creator>Martin, Stiles</dc:creator>
<dc:creator>Brieger, David</dc:creator>
<dc:creator>López de Sá, esteban</dc:creator>
<dc:creator>Gore, Joel M</dc:creator>
<dc:creator>Budaj, Andrzej</dc:creator>
<dc:creator>Gurfinkel, Enrique P</dc:creator>
<dc:creator>López-Sendón, José</dc:creator>
<dc:creator>Werff, Frans Van de</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Introducción y objetivos. Investigar la incidencia de hemorragias graves y la mortalidad hospitalaria en pacientes con infarto de miocardio y elevación del segmento ST (IAMCEST) en relación con la administración de tienopiridinas con o sin tratamiento trombolítico asociado. Métodos. Se estudió la incidencia de hemorragias graves y mortalidad hospitalaria en 14.259 pacientes consecutivos con IAMCEST. En total, 5.340 (38%) pacientes recibieron tratamiento con tienopiridinas, 3.007 (21%) recibieron fármacos trombolíticos y 2.044 (14%), ambos tipos de fármacos durante el periodo de hospitalización. Resultados. Las hemorragias graves fueron más frecuentes en los pacientes que recibieron tienopiridinas con o sin fármacos trombolíticos asociados (el 4,6 y el 4,1%, respectivamente) que en los pacientes que sólo recibieron fibrinolíticos (2,3%) o ninguno de los dos tipos de fármacos (2,8%) (p &lt; 0,001). En el análisis multivariable, ajustado para los factores de riesgo hemorrágico y cateterismo cardiaco o intervención coronaria percutánea, el tratamiento con tienopiridinas se identificó como un factor independiente de hemorragia (odds ratio [OR] = 1,68; intervalo de confianza [IC] del 95%, 1,23-2,31). La mortalidad intrahospitalaria fue menor en los pacientes que recibieron tienopiridinas, lo que se identificó como factor independiente relacionado con menor mortalidad (OR = 0,50; IC del 95%, 0,39-0,60). Conclusiones. El tratamiento con tienopiridinas se asoció con un aumento del riesgo de hemorragias, pero con mejor pronóstico intrahospitalario. Estos resultados, en pacientes no seleccionados con diagnóstico de IAMCEST y representativos de la práctica clínica diaria complementan, pero no reemplazan, la información derivada de ensayos clínicos en enfermos seleccionados y con distribución aleatoria del tratamiento (AU)</dc:description>
<dc:source>Rev Esp Cardiol;62(5): 501-509, mayo 2009. tab, graf</dc:source>
<dc:identifier>ibc-72662</dc:identifier>
<dc:title xml:lang="es">Evolución hospitalaria asociada al empleo de fibrinolíticos y tienopiridinas en pacientes con infarto agudo de miocardio y elevación del segmento ST. The Global Registry of Acute Coronary Events</dc:title>
<dc:subject>^d4634^s22045</dc:subject>
<dc:subject>^d30047</dc:subject>
<dc:subject>^d932^s22073</dc:subject>
<dc:subject>^d5478^s22073</dc:subject>
<dc:subject>^d35398^s22045</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d9395^s22057</dc:subject>
<dc:subject>^d5478^s22020</dc:subject>
<dc:subject>^d35398^s22066</dc:subject>
<dc:subject>^d6622^s22036</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d20174</dc:subject>
<dc:subject>^d27794</dc:subject>
<dc:subject>^d12162^s22020</dc:subject>
<dc:subject>^d12162^s22073</dc:subject>
<dc:subject>^d9395^s22032</dc:subject>
<dc:subject>^d28607</dc:subject>
<dc:subject>^d6622^s22080</dc:subject>
<dc:subject>^d9062</dc:subject>
<dc:subject>^d19059</dc:subject>
<dc:subject>^d3343^s22080</dc:subject>
<dc:type>article</dc:type>
<dc:date>200905</dc:date>
</metadata>
</record>
</ibecs-document>
